Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1

6(85.7%)

Phase 4

1(14.3%)

7Total

Phase 1(6)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03088111Phase 4Unknown

An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis

Role: lead

NCT01932242Phase 1Completed

Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers

Role: lead

NCT01932437Phase 1Completed

Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers

Role: lead

NCT01952444Phase 1Completed

Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers

Role: lead

NCT01929226Phase 1Completed

Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers

Role: lead

NCT01453907Phase 1Completed

Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers

Role: lead

NCT00829582Phase 1Completed

Intravenous Dose-Escalation Study With ETI-204 in Adult Volunteers

Role: lead

All 7 trials loaded